BLA 761278 · Chiesi Farmaceutici Spa
Lamzede
Velmanase Alfa-Tycv
NovelPriority reviewOrphanCDER novel approval, Feb 16, 2023: To treat non-central nervous system manifestations of alpha-mannosidosis
Last checked: Nov 20, 2026Latest source record: Feb 16, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Feb 16, 2023
Approved uses
1
Original approval plus efficacy supplements
Registered trials
9
5 Phase 3, 1 recruiting
FAERS reports
56
31 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SEVERE HYPERSENSITIVITY REACTIONS Hypersensitivity Reactions Including Anaphylaxis Patients treated with LAMZEDE have experienced hypersensitivity reactions, including anaphylaxis. Appropriate medical support measures, including cardiopulmonary resuscitation equipment , should be readily available during LAMZEDE administration. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue LAMZEDE immediately and initiate appropriate medical treatment. In patients with severe hypersensitivity reaction, a desensitization procedure to LAMZEDE may be considered [see Warnings and Precautions ( 5.1 )]. WARNING: SEVERE HYPERSENSITIVITY REACTIONS See full prescribing information for complete boxed warning. Hypersensitivity Reactions Including Anaphylaxis Appropriate medical support measures, including cardiopulmonary resuscitation equipment , should be readily...
What it is approved for
From the label in effect Feb 21, 2023.
1 INDICA TIONS AND USAGE LAMZEDE is indicated for the treatment of non-central nervous system manifestations of alpha-mannosidosis in adult and pediatric patients. LAMZEDE is recombinant human lysosomal alpha-mannosidase indicated for the treatment of non-central nervous system manifestations of alpha-mannosidosis in adult and pediatric patients. ( 1 )
Mechanism: Alpha-mannosidosis is a lysosomal storage disease that results from reduced activity of the enzyme alpha-mannosidase, caused by gene variants in Mannosidase Alpha Class 2B Member 1. Alpha-mannosidase catalyzes the degradation of accumulated mannose-containing oligosaccharides. The deficiency of alpha-mannosidase causes an intra-lysosomal accumulation of mannose-rich oligosaccharides in various tissues. Velmanase alfa-tycv provides an exogenous source of alpha-mannosidase. Velmanase alfa-tycv is internalized via binding to the mannose-6-phosphate receptor on the cell surface and transported...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 16, 2023 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLetterLabelReview
1 products under this application
- LAMZEDE · VELMANASE ALFA-TYCV 10MG · POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER, · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Velmanase Alfa" as an intervention, any sponsor and status, largest first.
- A Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-MannosidosisPivotal-lookingCompleted
Zymenex A/SIndustry
NCT01681953 · 25 participants · Start Aug 2012 · Primary completion May 2014
Drug: Lamazym; Placebo · For: Alpha-Mannosidosis
Sites: Copenhagen, Denmark; Bron, France; Paris, France · 6 sites in all
- Evaluation of Long-term Efficacy of Treatment With LamazymPivotal-lookingCompleted
Zymenex A/SIndustry
NCT02478840 · 18 participants · Start Feb 2015 · Primary completion Jun 2015
Drug: Lamazym · For: Alpha-Mannosidosis
Sites: Copenhagen, Denmark
- Lamazym Aftercare Study FR Designed to Provide Treatment for French PatientsPivotal-lookingCompleted
Chiesi Farmaceutici S.p.A.Industry
NCT01908712 · 13 participants · Start Aug 2013 · Primary completion Sep 30, 2022
Drug: Lamazym · For: Alpha-Mannosidosis
Sites: Bron, France
- Dose Finding Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosisStatus unknown
Zymenex A/SIndustry
NCT01285700 · 10 participants · Start Jan 2011 · Primary completion Jan 2012
Drug: Lamazym · For: Alpha Mannosidosis
Sites: Copenhagen, Denmark
- Long-term Efficacy and Safety of Lamazym for the Treatment of Patients With Alpha-MannosidosisCompleted
Zymenex A/SIndustry
NCT01681940 · 10 participants · Start Jan 2012 · Primary completion Aug 2012
Drug: Lamazym · For: Alpha-Mannosidosis
Sites: Brussels, Belgium; Copenhagen, Denmark; Córdoba, Spain · 4 sites in all
Zymenex A/SIndustry
NCT01268358 · 10 participants · Start Oct 2010 · Primary completion Jan 2011
Drug: Lamazym · For: Alpha Mannosidosis
- Lamazym Aftercare StudyPivotal-lookingCompleted
Chiesi Farmaceutici S.p.A.Industry
NCT01908725 · 8 participants · Start Jun 2013 · Primary completion Sep 30, 2022
Drug: Lamazym · For: Alpha-Mannosidosis
Sites: Copenhagen, Denmark
Chiesi Farmaceutici S.p.A.Industry
NCT02998879 · 5 participants · Start Dec 2016 · Primary completion Jul 2020
Drug: Velmanase Alfa (e.g. Lamazym) · For: Alpha-Mannosidosis
Sites: Vienna, Austria; Copenhagen, Denmark; Lyon, France · 6 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- product dose omission issue6
- product complaint5
- pyrexia5
- off label use4
- product administration interrupted4
- vomiting4
- abdominal pain3
- arthropathy3
- haemoglobin decreased3
- infusion related reaction3
- urticaria3
- blood creatinine increased2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2023 | 6 |
| 2024 | 17 |
| 2025 | 25 |
| 2026 | 8 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Lamzede (Velmanase Alfa-Tycv) · HCPCS J0217
2024 spending
$2.0M
Beneficiaries
n/a
65 claims
Per beneficiary
n/a
2024 ASP limit $442.00 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $2,049,467 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Extended long-term efficacy and safety of velmanase alfa treatment up to 12ߙyears in patients with alpha-mannosidosis.
Guffon N, Borgwardt L, Tylki-Szymaska A, et al. · J Inherit Metab Dis 2025 · Multicenter Study, Clinical Trial, Phase III
- Efficacy and safety of Velmanase alfa in the treatment of patients with alpha-mannosidosis: results from the core and extension phase analysis of a phase III multicentre, double-blind, randomised, placebo-controlled trial.
Borgwardt L, Guffon N, Amraoui Y, et al. · J Inherit Metab Dis 2018 · Clinical Trial, Phase III, Multicenter Study
- Long-term safety and efficacy of velmanase alfa treatment in children under 6ߙyears of age with alpha-mannosidosis: A phase 2, open label, multicenter study.
Guffon N, Konstantopoulou V, Hennermann JB, et al. · J Inherit Metab Dis 2023 · Multicenter Study, Clinical Trial, Phase II
- Comprehensive long-term efficacy and safety of recombinant human alpha-mannosidase (velmanase alfa) treatment in patients with alpha-mannosidosis.
Lund AM, Borgwardt L, Cattaneo F, et al. · J Inherit Metab Dis 2018 · Clinical Trial, Phase I, Clinical Trial, Phase II
Sponsor: Chiesi Farmaceutici Spa
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.